PortalPublikationenArsenic trioxide inhibits tumor cell growth in malignant rha...

Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1

Standard

Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1. / Kerl, Kornelius; Moreno, Natalia; Holsten, Till; Ahlfeld, Julia; Mertins, Julius; Hotfilder, Marc; Kool, Marcel; Bartelheim, Kerstin; Schleicher, Sabine; Handgretinger, Rupert; Schüller, Ulrich; Meisterernst, Michael; Frühwald, Michael C.

in: INT J CANCER, Jahrgang 135, Nr. 4, 15.08.2014, S. 989-95.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kerl, K, Moreno, N, Holsten, T, Ahlfeld, J, Mertins, J, Hotfilder, M, Kool, M, Bartelheim, K, Schleicher, S, Handgretinger, R, Schüller, U, Meisterernst, M & Frühwald, MC 2014, 'Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1', INT J CANCER, Jg. 135, Nr. 4, S. 989-95. https://doi.org/10.1002/ijc.28719

APA

Kerl, K., Moreno, N., Holsten, T., Ahlfeld, J., Mertins, J., Hotfilder, M., Kool, M., Bartelheim, K., Schleicher, S., Handgretinger, R., Schüller, U., Meisterernst, M., & Frühwald, M. C. (2014). Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1. INT J CANCER, 135(4), 989-95. https://doi.org/10.1002/ijc.28719

Vancouver

Kerl K, Moreno N, Holsten T, Ahlfeld J, Mertins J, Hotfilder M et al. Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1. INT J CANCER. 2014 Aug 15;135(4):989-95. https://doi.org/10.1002/ijc.28719

Bibtex

@article{92e4aa99a5a646e5869a4d8446eb9550,
title = "Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1",
abstract = "Rhabdoid tumors are highly aggressive tumors occurring in infants and very young children. Despite multimodal and intensive therapy prognosis remains poor. Molecular analyses have uncovered several deregulated pathways, among them the CDK4/6-Rb-, the WNT- and the Sonic hedgehog (SHH) pathways. The SHH pathway is activated in rhabdoid tumors by GLI1 overexpression. Here, we demonstrate that arsenic trioxide (ATO) inhibits tumor cell growth of malignant rhabdoid tumors in vitro and in a mouse xenograft model by suppressing Gli1. Our data uncover ATO as a promising therapeutic approach to improve prognosis for rhabdoid tumor patients.",
keywords = "Animals, Antineoplastic Agents, Apoptosis, Arsenicals, Cell Cycle, Cell Proliferation, Computational Biology, Gene Expression Profiling, Gene Expression Regulation, Gene Expression Regulation, Neoplastic, Hedgehog Proteins, Humans, Kruppel-Like Transcription Factors, Mice, Mice, SCID, Neoplasm Transplantation, Oxides, Prognosis, Rhabdoid Tumor, Signal Transduction, Transcription Factors, Zinc Finger Protein GLI1, Journal Article, Research Support, Non-U.S. Gov't",
author = "Kornelius Kerl and Natalia Moreno and Till Holsten and Julia Ahlfeld and Julius Mertins and Marc Hotfilder and Marcel Kool and Kerstin Bartelheim and Sabine Schleicher and Rupert Handgretinger and Ulrich Sch{\"u}ller and Michael Meisterernst and Fr{\"u}hwald, {Michael C}",
note = "{\textcopyright} 2014 UICC.",
year = "2014",
month = aug,
day = "15",
doi = "10.1002/ijc.28719",
language = "English",
volume = "135",
pages = "989--95",
journal = "INT J CANCER",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1

AU - Kerl, Kornelius

AU - Moreno, Natalia

AU - Holsten, Till

AU - Ahlfeld, Julia

AU - Mertins, Julius

AU - Hotfilder, Marc

AU - Kool, Marcel

AU - Bartelheim, Kerstin

AU - Schleicher, Sabine

AU - Handgretinger, Rupert

AU - Schüller, Ulrich

AU - Meisterernst, Michael

AU - Frühwald, Michael C

N1 - © 2014 UICC.

PY - 2014/8/15

Y1 - 2014/8/15

N2 - Rhabdoid tumors are highly aggressive tumors occurring in infants and very young children. Despite multimodal and intensive therapy prognosis remains poor. Molecular analyses have uncovered several deregulated pathways, among them the CDK4/6-Rb-, the WNT- and the Sonic hedgehog (SHH) pathways. The SHH pathway is activated in rhabdoid tumors by GLI1 overexpression. Here, we demonstrate that arsenic trioxide (ATO) inhibits tumor cell growth of malignant rhabdoid tumors in vitro and in a mouse xenograft model by suppressing Gli1. Our data uncover ATO as a promising therapeutic approach to improve prognosis for rhabdoid tumor patients.

AB - Rhabdoid tumors are highly aggressive tumors occurring in infants and very young children. Despite multimodal and intensive therapy prognosis remains poor. Molecular analyses have uncovered several deregulated pathways, among them the CDK4/6-Rb-, the WNT- and the Sonic hedgehog (SHH) pathways. The SHH pathway is activated in rhabdoid tumors by GLI1 overexpression. Here, we demonstrate that arsenic trioxide (ATO) inhibits tumor cell growth of malignant rhabdoid tumors in vitro and in a mouse xenograft model by suppressing Gli1. Our data uncover ATO as a promising therapeutic approach to improve prognosis for rhabdoid tumor patients.

KW - Animals

KW - Antineoplastic Agents

KW - Apoptosis

KW - Arsenicals

KW - Cell Cycle

KW - Cell Proliferation

KW - Computational Biology

KW - Gene Expression Profiling

KW - Gene Expression Regulation

KW - Gene Expression Regulation, Neoplastic

KW - Hedgehog Proteins

KW - Humans

KW - Kruppel-Like Transcription Factors

KW - Mice

KW - Mice, SCID

KW - Neoplasm Transplantation

KW - Oxides

KW - Prognosis

KW - Rhabdoid Tumor

KW - Signal Transduction

KW - Transcription Factors

KW - Zinc Finger Protein GLI1

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1002/ijc.28719

DO - 10.1002/ijc.28719

M3 - SCORING: Journal article

C2 - 24420698

VL - 135

SP - 989

EP - 995

JO - INT J CANCER

JF - INT J CANCER

SN - 0020-7136

IS - 4

ER -